Abstract P172: Prevalence of Reduced Estimated Glomerular Filtration and Albuminuria In Clinically Relevant Subgroups in a Representative Elderly Population in Iceland
Background: Chronic kidney disease is common in the elderly, but limited data are available describing the prevalence of the major components of chronic kidney disease - reduced glomerular filtration rate (eGFR) and kidney damage - in clinically important subgroups in this population.
Methods: Our study sample included 3173 adults (42% male, median [interquartile range] age 80 [76-83] years) from the second visit of the Age, Gene/Environment Susceptibility Reykjavik study (AGES-RS II, 2007-11). eGFR was estimated using the CKD-EPI 2012 creatinine-cystatin C equation and we defined reduced eGFR as an eGFR<60mL/min/1.73m2. Urine albumin and creatinine were used to calculate the albumin-to-creatinine ratio (ACR, mg/g). Kidney damage was evaluated as the presence of albuminuria, defined as an ACR>30mg/g. We estimated the prevalence of reduced eGFR and albuminuria in subgroups defined by age, sex, diabetes status, current smoking status, and body mass index. We compared prevalence estimates within subgroups using Chi-square tests and tests for trend across multi-category groups.
Results: Reduced eGFR was consistently more common than albuminuria across subgroups (Figure). The prevalence of reduced eGFR increased across age and BMI categories (both p-trend<0.001) and was higher in women (p=0.02) and in those with diabetes (p<0.001), but did not differ by smoking status (p=0.46). The prevalence of albuminuria was higher with age (p-trend<0.001), in participants with diabetes (p<0.001), in men (p<0.001), and in current smokers (p=0.004). In BMI groups, the prevalence of albuminuria was highest in those with a BMI<20 and was similar across the remaining BMI categories (p-trend=0.03).
Conclusion: The prevalence of reduced eGFR and albuminuria is high in the elderly, increases with advancing age, and is dependent on other demographic and clinical characteristics.
Author Disclosures: M.C. Foster: None. A. Okparavero: None. H. Tighiouart: None. V. Gudnason: None. O. Indridason: None. H. Gudmundsdottir: None. G. Eiriksdottir: None. L.A. Inker: H. Other; Modest; Dr Inker had a patent pending for novel metabolites to estimate GFR. A.S. Levey: H. Other; Modest; Dr Levey had a patent pending for novel metabolites to estimate GFR..
- © 2015 by American Heart Association, Inc.